Markets

3 Biotech Stocks That Are Soaring Higher

Three biotech stocks were among the market's best-performing companies last week. Two of them are highly speculative, clinical-stage biotech stocks that surged on optimism about drugs in their pipelines. The third is commercial stage big-cap biotech stock that is racking up profit thanks to a fast-growing cancer drug.

It's anyone's guess whether these three biotech stocks will continue their winning ways in the months and years to come, but I've prepared a slideshow below that highlights what you need to know about PTC Therapeutics , Tesaro , and Pharmacyclics and why each of them have recently surged by 25% or more.

This coming blockbuster will make every biotech jealous

The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .

The article 3 Biotech Stocks That Are Soaring Higher originally appeared on Fool.com.

Todd Campbell is long Pharmacyclics. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PTCT

Other Topics

Stocks